Value of CCNA1 promoter methylation in triaging ASC-US cytology

Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promoter methylation

Human papillomavirus (HPV) oncoproteins drive distinctive promoter methylation patterns in cancer. However, the underlying mechanism remains to be elucidated. Cyclin A1 (CCNA1) promoter methylation is strongly associated with HPV-associated cancer. CCNA1 methylation is found in HPV-associated cervical cancers, as well as in head and neck squamous cell cancer. Numerous pieces of evidence suggest...

Correlation of CCNA1 Promoter Methylation with Malignant Tumors: A Meta-Analysis Introduction

Epigenetic silencing of tumor suppressor genes by promoter methylation plays vital roles in the process of carcinogenesis. The purpose of this meta-analysis was to determine whether the aberrant methylation of cyclin A1 (CCNA1) may be of great significance to human malignant tumors. By searching both English and Chinese language-based electronic databases carefully, we tabulated and analyzed pa...

CCNA1 Promoter Methylation: A Potential Marker for Grading Papanicolaou Smear CIN Lesions

Cervical cancer is the second most common type of cancer in women in less developed country. In South-east Asia regions, there was 51,000 newly diagnosed case and 24,000 deaths in the year 2012 (GLOBOCAN, 2012). Notably, cervical cancer has the pathological feature of long precancerous phase and spanning years. In both developed and developing countries, the cytology-based method (Pap test) usi...

Atypical squamous cells: ASCUS is out! Now, ASC-US and ASC-H for reporting of cervical cytology.

Study of the role of siRNA mediated promoter methylation in DNMT3B knockdown and alteration of promoter methylation of CDH1, GSTP1 genes in MDA-MB -453 cell line

Promoter methylation is one of the main epigenetic mechanisms that lead to the inactivation of tumor suppressor genes during carcinogenesis. Due to the reversible nature of DNA methylation, many studies have been performed to correct theses epigenetic defects by inhibiting DNA methyltransferases (DNMTs). In this case novel therapeutics especially siRNA oligonucleotides have been used to specifi...